ArticleActa medica Philippina2026
Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Prenatal Disorders.
Article in Acta medica Philippina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Philippine Guidelines on Periodic Health Examination (PHEX) support the Universal Health Care Act by providing guidance on quality, accessible, and affordable screening services for Filipinos. Conditions that develop in the prenatal period are a major cause of neonatal deaths in the Philippines and account for 14% of deaths in children under five. Objectives: This guideline aims to provide evidence-based recommendations for screening prenatal disorders among asymptomatic, pregnant Filipino women. It also aims to equip general practitioners, obstetricsgynecology specialists, allied health professionals, patients, policymakers, regulatory agencies, and healthcare institutions with tools and guidance that facilitate informed, evidence-based healthcare decisions for pregnant women. Methods: The development of this CPG followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to CPG development recommended in the Department of Health (DOH) Manual. Recommendations were finalized using the Evidence-to-Decision (EtD) framework. Evidence Review Experts conducted a systematic literature search and critically appraised recent local and international clinical guidelines. When necessary, they conducted Results: Eleven recommendations for different screening strategies to improve the health outcomes of pregnant women and neonates were developed. This CPG contains recommendations for the screening for maternal thyroid disease, gestational diabetes mellitus, group B Streptococcus infection, fetal aneuploidy, risk for preeclampsia, iron deficiency anemia, and undernutrition, and conducting cervical length measurements, first-trimester ultrasound, and second-trimester ultrasound. Conclusion: This CPG provides 11 evidence-based recommendations. Applicability in the local setting was carefully considered through the involvement of different stakeholders. The recommendations herein shall hold until new evidence on screening, diagnosing, or managing various risk factors and diseases emerges, or contingencies dictate updating this CPG. This guideline will be updated after three (3) years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.